Core Insights - Ashland reported revenue of $405 million for the quarter ended December 2024, a decrease of 14.4% year-over-year, and EPS of $0.28, down from $0.45 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $433.23 million, resulting in a surprise of -6.52%, while the EPS exceeded the consensus estimate of $0.20 by 40% [1] Revenue Performance - Revenue from Intermediates was $33 million, slightly below the estimated $34.30 million, showing no change from the previous year [4] - Revenue from Specialty Additives was $115 million, slightly below the estimated $115.26 million, reflecting a decline of 5.7% year-over-year [4] - Revenue from Personal Care reached $134 million, slightly above the estimated $133.90 million, marking an increase of 3.9% compared to the previous year [4] - Revenue from Life Sciences was $134 million, significantly below the estimated $160.78 million, representing a year-over-year decline of 33% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $28 million, below the estimated $37.61 million [4] - Adjusted EBITDA for Intermediates was $6 million, slightly below the estimated $6.63 million [4] - Adjusted EBITDA for Specialty Additives was $13 million, exceeding the estimated $7.58 million [4] - Adjusted EBITDA for Personal Care was $30 million, surpassing the average estimate of $22.97 million [4] Stock Performance - Ashland's shares returned +0.3% over the past month, compared to a +0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Ashland (ASH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this chemical company would post earnings of $1.33 per share when it actually produced earnings of $1.26, delivering a surprise of -5.26%.Over the last four quarters, the company has ...

"Since announcing the sale agreement for our Avoca business, we are nearing the final stages of our portfolio optimization activities. The last stage will be to fully implement our $30 million cost reduction plan to offset the stranded costs and gross profit loss from the sale of the nutraceutical business," said Guillermo Novo, chair and chief executive officer of Ashland. "Ashland continues to demonstrate strategic progress and operating discipline amid softer market conditions, generally consistent with ...

Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income ...

Analysts on Wall Street project that Ashland (ASH) will announce quarterly earnings of $0.20 per share in its forthcoming report, representing a decline of 55.6% year over year. Revenues are projected to reach $439.38 million, declining 7.1% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 5.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Befo ...

Content Summary - The article promotes joining iREIT on Alpha for in-depth research on REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives, highlighting 438 testimonials with mostly 5-star ratings and offering a FREE 2-week trial [1] - President Trump was officially sworn in as the 47th President of the United States, making history as noted by The Wall Street Journal [1] Analyst's Disclosure - The analyst holds a beneficial long position in REXR through stock ownership, options, or other derivatives, and the article reflects their personal opinions without compensation (other than from Seeking Alpha) [2] Seeking Alpha's Disclosure - Seeking Alpha clarifies that past performance does not guarantee future results and does not provide investment recommendations or advice, with views expressed not necessarily reflecting those of Seeking Alpha as a whole [3]

Wall Street expects a year-over-year decline in earnings on lower revenues when Ashland (ASH) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 28, 2025, might help the stock move higher if these key numbers are better than expecta ...

Ashland Inc (ASH) is a Zacks Rank #5 (Strong Sell) after the company missed the Zacks Consensus Estimate when the last reported. The company is in the specialty chemicals space and services many industries such as the automotive and construction sectors. This article will look at why this stock is a Zacks Rank #5 (Strong Sell) as it is the Bear of the Day.Description                        Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatin ...

WILMINGTON, Del., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, January 28, 2025. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 29. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://in ...

Stocks Added to Zacks Rank 5 (Strong Sell) List - 89bio Inc (ETNB) is a clinical-stage biopharmaceutical company with a 38 8% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - Altice USA Inc (ATUS) is a broadband communications and video services provider with a 250% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - Ashland Inc (ASH) is an additives and specialty ingredients provider with a 16 2% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [2]